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Abstract
Background: Vulvar Paget disease is a rare skin disorder, which is most common in postmenopausal Caucasian women. They
usually present with an erythematous plaque that may show fine or typical “cake icing” scaling or ulceration that may cause
itching, pain, irritation, or a burning sensation. Although most cases are noninvasive, vulvar Paget disease may be invasive or
associated with an underlying vulvar or distant adenocarcinoma. The histological evidence of so-called “Paget cells” with abundant
pale cytoplasm in the epithelium confirms the diagnosis. The origin of these Paget cells is still unclear. Treatment of choice is
wide local excision with negative margins. Obtaining clear surgical margins is challenging and may lead to extensive and mutilating
surgery. Even then, recurrence rates are high, ranging from 15% to 70%, which emphasizes the need for new treatment options.
A number of case reports, retrospective case series, and one observational study have shown promising results using the topical
immune response modifier imiquimod.
Objective: This study aims to investigate the efficacy, safety, and immunological response in patients with noninvasive vulvar
Paget disease using a standardized treatment schedule with 5% imiquimod cream.
Methods: Topical 5% imiquimod cream might be an effective and safe treatment alternative for vulvar Paget disease. The Paget
Trial is a multicenter observational cohort study including eight tertiary referral hospitals in the Netherlands. It is ethically approved
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by the Medical-Ethical Committee of Arnhem-Nijmegen and registered in the Central Committee on Research Involving Human
Subjects (CCMO) Register by as NL51648.091.14. Twenty patients with (recurrent) noninvasive vulvar Paget disease will be
treated with topical 5% imiquimod cream three times a week for 16 weeks. The primary efficacy outcome is the reduction in
lesion size at 12 weeks after end of treatment. Secondary outcomes are safety, immunological response, and quality of life. Safety
will be assessed by evaluation of adverse events and tolerability of treatment. To evaluate the immunological response, various
immunological markers will be tested on biopsy specimens taken before, during, and after treatment. Quality of life will be
assessed with three questionnaires taken before, during, and after treatment.
Results: First results are expected in the summer of 2018.
Trial Registration: ClinicalTrials.gov NCT02385188; https://clinicaltrials.gov/ct2/show/NCT02385188 (Archived by WebCite
at http://www.webcitation.org/6sXygHuhP).
(JMIR Res Protoc 2017;6(9):e178)   doi:10.2196/resprot.7503
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Introduction
Cutaneous Paget disease was first described in a series of
patients with nipple ulceration and an underlying breast
carcinoma. This became known as mammary Paget disease
(MPD) [1]. When the same condition was reported on the
scrotum and vulva, these were named extramammary Paget
disease (EMPD) [2,3].
The presence of so-called Paget cells in the basal layers of the
epithelium is pathognomonic for this rare disease. The origin
of these large cells with abundant clear, pale cytoplasm, which
often contain mucin, remains unclear. The most common
hypothesis is that Paget cells originate from adnexal structures,
such as apocrine glands or multipotent stem cells in the basal
layer of the epidermis [4,5]. Other theories suggest the
anogenital area contains mammary-like glands or that Toker
cells, also seen in the nipple in mammary Paget disease, are
precursor cells for EMPD [6-8].
The incidence rate of EMPD is 0.11 per 100,000 person-years,
based on an epidemiological study with data of the Netherlands
Cancer Registry [9]. Vulvar Paget disease (VPD) causes pain,
itching, or a burning sensation, and a skin lesion, which can be
described as a scaling, erythematous plaque that sometimes
shows ulceration. VPD typically presents in postmenopausal
Caucasian women [8].
Vulvar Paget disease can be divided into primary VPD, which
is cutaneous, and secondary VPD, which is noncutaneous.
Textbox 1 illustrates the different types of VPD [10].
Vulval Paget disease is associated with different malignancies,
mainly an underlying vulvar, intestinal, or urological
malignancy, and breast cancer. Approximately 20% of patients
are reported to have an associated malignancy in their history.
Therefore, screening for underlying carcinoma is advised,
although there is no evidence for screening and no consensus
on the extent of the additional diagnostic procedures [11,12].
Historically, the treatment of choice for VPD is wide local
excision with clear margins, which is not always easy to realize
on the vulva. Because Paget cells are found widely spread
throughout the anogenital area, it is almost impossible to obtain
clear surgical margins [13,14]. The recurrence rates of VPD are
high: 15% to 70% independent of margin status. The risk of
recurrence is highest in the first year after treatment [15]. To
improve obtaining clear surgical margins, Mohs microsurgery
has been evaluated for treatment of VPD. In Mohs microsurgery,
the lesion is excised and the entire margin is examined
immediately [16]. In case the margin is not clear, the excision
is repeated, enlarging the circumference until the margins are
clear. This technique may lead to lower recurrence rates [17].
However, large vulvar excisions may require plastic
reconstruction.
Extensive vulvar surgery can cause permanent mutilation and
functional impairment [18-22]. To address this problem,
alternative treatment options such as photodynamic therapy,
radiotherapy, chemotherapy, laser treatment, and recently topical
5% imiquimod cream have been used in patients with VPD with
varying degrees of success [23-30].
Topical 5% imiquimod cream is an immune response modifier.
It binds to toll-like receptor 7, inducing an innate and
cell-mediated immune response [31]. It has antiviral and
antitumor properties and is registered for the treatment of
condylomata acuminata, actinic keratosis, and superficial basal
cell carcinomas. Imiquimod also has shown to be effective for
human papilloma virus-induced usual vulvar intraepithelial
neoplasia [32,33]. The mechanism of action of imiquimod and
local immunity in VPD are not known.
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Textbox 1. Different types of vulvar Paget disease.
Primary EMPD (cutaneous)
Type 1a: associated with noninvasive, intraepithelial disease
Type 1b: associated with invasive disease
Type 1c: associated with an underlying adenocarcinoma
Secondary EMPD (noncutaneous)
Type 2: EMPD originates from intestinal adenocarcinoma
Type 3: EMPD originates from urothelial carcinoma
More recently, a number of case reports, case series, and one
observational trial that reported on the use of topical 5%
imiquimod cream for VPD showed that imiquimod may be an
effective treatment option [34,35]. A systematic review also
concluded it is an effective alternative for VPD [36]. However,
most studies described limited numbers of patients, various
treatment schedules, and short follow-up periods. Therefore, it
is impossible to pool data from previous studies to make final
conclusions about the efficacy. The authors of the systematic
review also mentioned the risk of publication bias: only positive
results may be published retrospectively [36].
Objective
The objective of this study is to assess the clinical efficacy,
safety, and local immunity of topical 5% imiquimod cream in
patients with noninvasive VPD.
Methods
Study Design
This study is a multicenter, prospective, open-label observational
cohort study in patients with histologically proven, noninvasive
VPD. Patients will be treated with topical 5% imiquimod cream
three times a week for 16 weeks, with follow-up of one year
after the end of treatment.
Study Setting
Because VPD is rare, with an estimated incidence of four to
seven cases per year in the Netherlands, the trial will be carried
out in seven tertiary referral hospitals with a vulvar clinic in the
Netherlands. Vulvar clinics are outpatient multidisciplinary
clinics with participation of both gynecologists and
dermatologists who are specialized in disorders of the vulva.
Participating centers are Antoni van Leeuwenhoek, Netherlands
Cancer Institute, Amsterdam; Catharina Ziekenhuis, Eindhoven;
Erasmus Medical Center, Rotterdam; Leiden University Medical
Center; Radboudumc, Nijmegen; University Medical Center
Groningen; and University Medical Center Utrecht.
Participants
All patients with histologically proven noninvasive cutaneous
VPD visiting or referred to a participating clinic will be asked
to participate in this study. We estimate to include one patient
per center per year because of the rarity of the disease.
Inclusion criteria are noninvasive VPD (primary or recurrence
after earlier surgery or imiquimod treatment more than 6 months
previously), age 18 years and older, and willing and able to
comply with the protocol and provide informed consent in
accordance with institutional and regulatory guidelines. Most
patients are expected to be elderly, postmenopausal women,
who may suffer from comorbidities. All patients will be
instructed on how to apply the imiquimod cream by their
clinician, according to the leaflet provided by the manufacturer,
and using a mirror. If the patient is physically unable to apply
the cream, a health care provider (eg, a nurse at the nursing
home or via domiciliary care) will receive written instructions.
If the patient consents, a printed photograph in which the
affected skin is marked will be provided. Main exclusion criteria
are current invasive VPD, underlying adenocarcinoma, and
treatment of the vulva with topical 5% imiquimod cream during
the last 6 months.
Sample Size
Based on the estimated incidence of VPD in the Netherlands,
viability is set at 20 inclusions. Our sample size considerations
are based on the response rate. The primary outcome variable
is the response at 12 weeks after end of treatment with topical
5% imiquimod cream. The only observational study on this
topic, at time of conception of this trial, reported a response in
9 of 10 women [35]. Assuming a complete response rate of
80%, a cohort size of 20 patients is sufficient to estimate the
complete response rate with a standard error of 9%, using the
normal approximation for the binomial distribution. Because
we presume that the dropout rate will not exceed 20%, a
maximum of 25 patients will be included. When 20 patients
have been treated with topical 5% imiquimod cream for at least
8 weeks, we will stop recruitment.
Study Intervention
All patients will be treated with topical 5% imiquimod cream
three times a week for 16 weeks. This treatment schedule is
based on the treatment schedule for condylomata acuminata and
on a previous randomized controlled trial of imiquimod 5% for
usual vulvar intraepithelial neoplasia [31,33]. The healthy skin
around the visible lesion can be protected with an indifferent
basic ointment. Patients are allowed to use topical 3% lidocaine
in Vaseline ointment if they experience pain at the application
site. There must be a 1-hour interval between the application of
different topical agents. Patients are also allowed to use
paracetamol. In case of severe pain, when paracetamol and 3%
lidocaine ointment are insufficient, it is permitted after
consultation with the clinician to stop the treatment with topical
5% imiquimod cream for one week at a time. Patients are
allowed to stop/delay treatment for a total of 3 weeks within
the assigned treatment period.
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Table 1. Study schedule presenting an overview of all study activities.
68 w52 w40 w28 w16 w10 w4 wBaseline0 wStudy activities
Before treatment
XMapping and mammography
XWritten informed consent
XRequire histological samples (incl. mapping) and mammography results
from referring hospital
StopStartImiquimod 5% cream
XConsultation by phone
XXXXXXXConsultation at outpatient clinic of involved research clinic, containing:
XXXXVulvar examination, measurement and photo documentation
XXXXXXXXVAS score
XXXTolerability questionnaire
XXXBiopsy
XXXEQ5D
XXXDLQI
XXXFSDS
XXXReview patient diary
In case of a suspected secondary bacterial infection, fucidin
cream or ointment 20 mg/g will be prescribed. The patient will
apply the fucidin cream or ointment three times a day, according
to the prescription. No other local products than imiquimod
cream, lidocaine, indifferent moisturizers, or fucidin are allowed
to be applied at the lesion site. On an individual basis, other
topical products will be considered as a protocol violation.
Study Schedule
Patients will visit the clinic seven times during the study; the
final visit will be 1 year after the end of treatment (Table 1).
One consultation will take place by telephone. During these
consultations, pain will be measured by means of the visual
analog scale (VAS) score for pain. Pain, burning, and itching
will be asked on a four-point Likert scale. During the visits, the
clinical response will be evaluated by vulvar examination and
bidimensional measurement of the visible lesions. The
histological effect will be assessed by pathological assessment
of the presence of Paget cells in the biopsy sample(s) taken 12
weeks after the end of treatment. All biopsy samples taken
before, during, and after treatment will be taken around the same
location. The site of the first biopsy is most likely the most
evident lesion, causing a clinically visible lesion. The site of
this biopsy will be recorded in the case report file to ensure
other biopsies will be taken at the same area. Quality of life will
be assessed before, during, and after treatment using three
questionnaires on general health (EQ-5D), dermatological
quality of life (Dermatology Quality of Life Index [DLQI]),
and (if applicable) sexual functioning (Female Sexual Distress
Scale [FSDS]).
Safety will be evaluated by documentation of all adverse effects,
recorded by the clinician and by the patient in the patient diary.
The immunological effect will be assessed by comparing the
results of additional immunohistochemistry stains performed
on all three samples taken around the same location at baseline,
4 weeks after start of treatment, and 12 weeks after end of
treatment. All biopsies will be taken at approximately the same
location to ensure the local microenvironment is as similar as
possible in all samples. There are limited data on the tumor
microenvironment in VPD; we are currently performing a
separate pilot study to investigate the parameters in the immune
infiltrate in VPD. We are investigating which immune cells are
present in VPD, and will use this knowledge to further explore
which immune cells respond to the topical imiquimod cream
and the role they play in the origin and treatment of VPD. The
results of this separate pilot study will be used to decide which
markers will be investigated in the samples collected in the
Paget Trial.
Study Endpoints
The main study outcome is clinical response. This will be
assessed by determination of the reduction in lesion size 12
weeks after the end of treatment. This will ensure any local skin
effects caused by treatment will be healed at time of
examination. All measurements during the study will be
conducted by the same trained and experienced local clinician.
Photographs for documentation will be taken with a ruler
alongside the lesions. The comparison between the lesion size
at the start of treatment and 12 weeks after the end of treatment
can lead to the following outcomes:
1. Complete response: defined as disappearance of the lesion
and histological confirmation of disappearance;
2. Partial response: defined as decrease by ≥50% of total lesion
size;
3. No response: defined as <50% decrease of total lesion size;
or
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4. Progressive disease: defined as ≥25% increase of total lesion
size or progression into invasive disease and/or
adenocarcinoma.
Secondary outcomes are the safety, quality of life, and the
assessment of local immunological response. These outcomes
will be assessed according to the following criteria:
1. Safety: all adverse events that occur during the study will
be collected by the clinician at every consultation (at the
clinic or via telephone) and by the patient using a
standardized patient diary.
2. Quality of life: results of the three questionnaires (EQ-5D,
DLQI, and, if applicable, FSDS) taken before, during, and
after treatment will be compared.
Local immunological response will be assessed by a set of
markers, to be determined, in tissue samples obtained by vulvar
biopsy before, during, and after treatment.
Statistical Analysis:
An intention-to-treat (ITT) and per protocol (PP) analysis will
be performed. The population included in the ITT analysis is
defined as all patients that have started treatment with topical
5% imiquimod cream. The PP analysis will include patients that
have completed treatment with topical 5% imiquimod cream
according to protocol. Two-tailed P values <.05 will be
considered statistically significant. Our primary study parameter
is the clinical response to topical 5% imiquimod cream. Twelve
weeks after the end of treatment, the clinician will examine the
vulva of the patient and assign the patient in one of the response
categories as defined previously. Estimates of the percentage
responders per response category will be presented with
corresponding 95% confidence intervals. The relation between
treatment duration and dose versus response will be explored.
Safety will be analyzed in a descriptive manner, presenting all
adverse events (local and systemic) in all participants treated
with topical 5% imiquimod cream. Also, the use of painkillers,
lidocaine ointment, and discontinuation of treatment will be
reported.
Quality of life will be assessed by three questionnaires. The
EQ-5D results will be converted to the crosswalk index values,
using the Crosswalk Index Value Calculator [37]. The DLQI
results will be categorized according to the instruction manual,
ranging from “no effect at all on patient’s life” to “extremely
large effect on patient’s life” [38]. The result of the FSDS is the
sum of the answers. Descriptive statistics will be used to present
the change outcomes during treatment versus before treatment,
and after treatment versus before treatment. A subanalysis of
responders and nonresponders will be conducted.
The immunological results will be counted and compared
between the different biopsy samples. These data will be
reported in a descriptive manner.
Ethics
This study will be conducted according to the principles of the
Declaration of Helsinki (2008) and the Medical Research
Involving Human Subjects Act (Dutch: WMO). The protocol
has been medical-ethically approved by the Medical-Ethical
Committee of Arnhem-Nijmegen to be conducted in all seven
centers (NL51648.091.14). Before enrollment to the study,
written informed consent will be obtained from all patients.
Results
The study opened for enrollment in January 2015. Currently,
17 patients are participating in this trial. The first results are
expected in the summer of 2018.
Discussion
Currently, this study is the first prospective study examining
the clinical efficacy of topical 5% imiquimod cream in patients
with noninvasive VPD using a standardized treatment schedule
over 16 weeks. In addition, this study will also be the first to
investigate the safety, quality of life, and immunological
response of 5% imiquimod cream therapy in patients with VPD.
Until now, about 25 retrospective case series have been
published on this topic. These studies show high success rates.
The effectiveness of topical 5% imiquimod cream for VPD in
these cases might be overrated due to publication bias in these
retrospective cases. Most of the retrospective series have used
different treatment schedules. The prospective trial of Marchitelli
et al [35] used a different treatment schedule per patient. In most
case studies, treatment was continued until the patient obtained
a complete response. The pilot study by Cowan et al [34]
investigated the clinical response after 12 weeks of treatment
in eight patients with noninvasive VPD. Patients applied the
cream three times a week. Six patients had a clinical and
histological complete response; the other two had a partial
response with histological persistence. In our study, all 20
consecutive patients will be treated according to the same
treatment schedule: three times a week for 16 weeks. Currently,
there are no guidelines for topical 5% imiquimod treatment for
VPD. We based the treatment schedule on the treatment schedule
for condylomata acuminata because this is a registered indication
and therefore we consider this treatment schedule to be safe for
genital skin [31]. Furthermore, VPD may be considered a vulvar
premalignancy, and the same treatment schedule is used in a
previous randomized controlled trial of imiquimod 5% for usual
vulvar intraepithelial neoplasia [33].
There are very limited data concerning the influence of VPD
on everyday life of the patient. It is reported that vulvar surgery
may contribute to decreased quality of life and sexual
functioning compared to healthy patients. As VPD has high
recurrence rates, we assume (repetitive) surgical treatment may
have significant psychosexual effects on patients. Topical
treatment with 5% imiquimod cream will not induce scarring
nor will it alter the anatomy of the vulva. Because there is a lack
of data on this specific topic, we will investigate quality of life
with three different questionnaires before, during, and after
treatment.
The mechanism of action and immunological effects of 5%
imiquimod cream in VPD are uncertain. It is likely that
imiquimods’ immune modulating effect induces a local immune
response resulting in clearance of the Paget cells. Investigating
the immunological response in biopsy specimens taken before,
during, and after treatment will provide insight in the local
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effects of imiquimod in the skin and also in the underlying
mechanisms of action. Unfortunately, there is no current
literature on this topic. Therefore, we are conducting a pilot
study, investigating the microenvironment of VPD, to assess
which markers may be valuable in understanding the
immunological response in VPD.
In conclusion, VPD remains an elusive disease. Surgery has
been the treatment of choice for over a century. Due to high
recurrence rates and the vulnerable patient population affected
by the disease, there is a need for other less-invasive treatment
options. Topical 5% imiquimod cream may be an attractive
alternative. Our trial will investigate the clinical efficacy of
topical 5% imiquimod cream in 20 patients with a standardized
treatment schedule. This study will also evaluate the safety,
quality of life, and immunological response while using 5%
imiquimod cream.
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